SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C
http://www.w3.org/2000/01/rdf-schema#comment
"In patients with non-small-cell lung cancer treated with nivolumab worse pretreatment performance status and higher carcinoembryonic antigen were associated with inferior progression-free survival."
xsd:string
http://purl.uniprot.org/uniprot/#_B923E49337C406C5DB0568D3EBC2AB66085FA38DE7A20F0F10301D6848893B67EF38CDD2BAD88F129054C18357FE5022
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C
http://purl.uniprot.org/uniprot/Q53G30
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C
http://purl.uniprot.org/uniprot/#_Q53G30-mappedCitation-29277824
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6C242F44C95F35021A05A98B4CAE6294D129D1D5E8D44048E906C8864FFE5F581F7FCCEE07800584ED5CC463A13D514C